key: cord-0812924-vr5flvna
authors: Pettoello-Mantovani, Massimo; Cardemil, Cristina; Cohen, Robert; Lev, Corinne; Giardino, Ida; Indrio, Flavia; Somekh, Eli
title: Importance of COVID-19 Vaccination in Children: viewpoint and recommendations of the Union of European National Societies of Pediatrics
date: 2021-12-30
journal: J Pediatr
DOI: 10.1016/j.jpeds.2021.12.066
sha: 8d0932db2f93a9dd234e137fe54b88ac0bdbde30
doc_id: 812924
cord_uid: vr5flvna

nan

Administration 1 (FDA) and the European Medicine Agency 2 (EMA) have been shown to be safe and effective 3, 4 in the adult population at preventing severe disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide 5, 6 . The use of COVID-19 vaccination in children aged 12-17 years old has been the subject of extensive debate, as the assessment of risks and benefits was considered more complex than in adults 7,8 . Different circumstances were taken into account including common reactions, infrequent serious side effects, possible impact on routine immunization programs, as well as vaccine supply and cost of vaccination 9 . However, COVID-19 vaccines for individuals of this age group were authorized, initially for emergency use and later approved by the stringent regulatory authorities FDA and EMA, and have since been adopted with widespread use in several countries worldwide 10 . Additionally, both the FDA and EMA, in October/November 2021 have authorized the use of COVID-19 vaccines in children 5-11 years of age. Their approval followed a thorough evaluation process demonstrating the same high standards of quality, safety, immunogenicity and efficacy observed in the older populations 11,12 . COVID data tracking indicates that in the US 20.1% of the 5-11yo population have received at least one dose of COVID-19 vaccine by December 16th. The percentage of fully vaccinated subjects in the 5-11yo group is 11.3%; 62.3% of adolescents 12-17yo have received at least one dose of COVID-19 vaccine 4 .

In Europe the debate over the extension of the use of COVID-19 vaccine in children <17 years old is ongoing. The 27 member states of the European Union showed different views and adopted divergent policies. It is unclear whether a unitary position will eventually be taken by the EU and non-EU countries on the use of COVID-19 vaccination in individuals <17 years of age. In the Approvals by regulatory authorities in the US and Europe were based on evidence that the efficacy and immunogenicity of these vaccines are as high as those in older individuals and show rare serious adverse effects 30 . Myocarditis associated with mRNA COVID-19 vaccines is a sporadic adverse event predominantly seen in male adolescents and young adults following the second vaccine dose, which has raised concern about this risk in younger children. However, based on available data from the years preceding COVID-19, the risk of vaccine-associated myocarditis in 5-11-year-olds is expected to be extremely low compared with adolescents and young adults, in whomsuch risk is already low 36 .

We still do not have long term outcome data on myocarditis following vaccination. However, preliminary survey data at three months following diagnosis showed that 52% reported no symptoms within the prior two weeks 37,38 . The advantages of vaccination are considered to largely outweigh this risk, as the occasional cases of myocarditis associated with COVID-19 vaccination are predominantly mild and the risk of myocarditis following COVID-19 is higher than the risk of myocarditis after COVID-19 vaccination 37,38,39,40 .

The rare cases of MISC reported in adults following COVID-19 vaccination advised the importance of monitoring for this possible adverse event in children 5-11 years old.. However, data from vaccine trials in children <12 years old have not identified any potential signal triggering this event 39 . It is also important to take into account that the number of children 5-11 years old who have died due to J o u r n a l P r e -p r o o f COVID-19 during the pandemic, is higher than the mortality rates of the infections for which children were routinely vaccinated before COVID-19 vaccines were made available, including meningococcal disease, measles, varicella and rotavirus 36 vaccination in children and adolescents who do not have contraindications using a COVID-19 vaccine authorized for use for their age 45 . EPA-UNEPSA recommends the implementation of COVID-19 vaccination programs in these age groups 46 in order to protect children and adolescents' health and allow them to fully engage in all of the activities that are essential for their full development and wellbeing 47, 48 . Vaccinated children and adolescents would not be exposed to the adverse mental and behavioral consequences associated with isolation, quarantine and missing of school 49 .

In the EU, data from December 2021 show a 96% weekly increase of children hospitalized with laboratory-confirmed COVID-19, of whom 69% were < 4 years old, strongly suggesting the importance of COVID-19 vaccination in younger children 49 . Vaccine trials in children ages 6 months to 5 years are underway in the USunder careful supervision by the FDA and key data are expected to be released in the coming months.

J o u r n a l P r e -p r o o f

US Food and Drug Administration

Efficacy and Safety of COVID-19 Vaccines in Phase III Trials: A Meta-Analysis. Vaccines

Demographic Trends of People Receiving COVID-19 Vaccinations in the United States

Effectiveness of COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight

Prevention and attenuation of Covid-19 with the BNT162b2 and mRNA-1273 vaccines

COVID-19 Vaccines in Children and Adolescents

Viewpoint of the European Pediatric Societies over Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Vaccination in Children Younger Than Age 12 Years Amid Return to School and the Surging Virus Variants

Changes in Routine Pediatric Practice in Light of Coronavirus 2019 (COVID-19)

Fostering Resilience in Children: The Essential Role of Healthcare Professionals and Families

Behavioral and Emotional Disorders in Children during the COVID-19 Epidemic

Federazione Italiana Aziende Sanitarie e Ospedaliere. Covid, nei reparti ordinari +16,7% di no vax e -2% di vaccinati